Compare Ascendis Pharma A/S (ASND) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Alphabet Inc Class A — how do they compare? Ascendis Pharma A/S trades at $255.41 (market cap $16.67B), while Alphabet Inc Class A trades at $343.65 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 251.9× Ascendis Pharma A/S's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GOOGL | |
|---|---|---|
Market Cap | $16.67B | $4.20T |
Sector | Health | Media |
52-Week High | $277.18 | $402.62 |
52-Week Low | $189.74 | $199.32 |
Enterprise Value | $17.04B | $4.09T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Alphabet (GOOGL) trades at $344.00, down 3.78% on the day, with technical indicators showing bearish momentum below key resistance at $347. Fundamentally, the company demonstrates strong profitability with 54.77% net income margin and consistent earnings beats, though valuation multiples remain elevated with P/E at 17.25. Recent developments include YouTube subscription price increases and continued AI infrastructure investments.
The stock presents a compelling long-term opportunity given strong analyst consensus (85% buy ratings) and $426.28 price target, representing 24% upside. Key risks include antitrust scrutiny and tech sector rotation pressures, but Alphabet's AI leadership and diversified revenue streams support growth prospects despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
